Specialty Pharmacy

The staff at all CVS Caremark Specialty Pharmacy locations are being trained to use PAN's Specialty Pharmacy Portal to help patients quickly access financial support to cover medication costs that may not be covered by insurance.

Magellan Pharmacy Solutions, a specialty health care management organization, has launched Total Drug Solutions, an integrated approach to managing all drugs - oral, injectable and infusible.

The lifetime revenue potential of orphan drugs far exceeds the financial potential of other medications, according to a recent report conducted by researchers from Thomson Reuters Life Sciences Professional Services and Pfizer.

Breakthrough cancer pain-episodes of intense pain experienced by many cancer patients despite around-the-clock treatment with opioids-can be effectively managed with a fentanyl-based oral spray.

The Johnson & Johnson Patient Assistance Foundation, Inc (JJPAF) announced that it has started to use a new common patient assistance program application for the HIV medicines it offers, streamlining for patients in the United States the process of applying for HIV medicines from multiple patient assistance programs.

Genzyme, a Sanofi company, announced that the FDA has approved Aubagio (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

Although many of the anticompetitive claims levied against the ESI-Medco merger did not survive a recent United States District Court ruling, the claim regarding the sale of specialty pharmaceuticals remains intact.

In honor of National Ovarian Cancer Month and Gynecologic Cancer Month, both taking place in September, Walgreens and Ferring Pharmaceuticals Inc announced a collaboration to provide free access to certain fertility medications and educational resources as part of Ferring's h.e.a.r.t. BEAT program.

The Anti-Infective Drugs Advisory Committee (AIDAC) to the FDA voted 13 to 1 that there was adequate evidence of efficacy and safety to support the use of tobramycin inhalation powder (TIP) for the management of cystic fibrosis (CF) patients whose lungs contain bacteria called Pseudomonas aeruginosa (Pa).

Pfizer Inc recently announced the FDA has approved Bosulif (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

The FDA recently approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.

Pluristem Therapeutics, Inc, a leading developer of placenta-based cell therapies, today announced that it has filed the necessary documents requesting that the FDA grant orphan drug status to its PLacental eXpanded (PLX) cells for the treatment of aplastic anemia.

Stribild, previously known as the Quad, has been approved by the FDA to treat HIV-1 infection in adults who are starting HIV treatment for the first time.

Scientists show a renewed interest in latrepirdine as a treatment for a number of neurodegenerative disorders after experiments with the drug exhibited improved memory function in animal models.

Diplomat Specialty Pharmacy announced that, for the fourth consecutive year, they earned a position on Inc. magazine's exclusive, annual ranking of the fastest-growing private companies in America.

The business and science of innovation are challenged by a recent article in British Medical Journal entitled "Pharmaceutical research and development: what do we get for all that money?"

Dr. D'vorah Graeser weighs in on the increasingly popular practice of using pay-for-delay arrangements to settle disputes over pharmaceutical patent ownership.

The new platform provides patients with a reliable place to go for information about their disease state and specialty medications.

BioPlus Specialty Pharmacy announces the hiring of Karen Bowe as the national director of hemophilia, northeast, to better meet the needs of its best-in-class Bleeding Disorders Program.

Continuing medical education company PER hosts congress conducted by leading faculty.

Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc announced the launch of patient management programs for Sprycel (dasatinib) patients with a select group of specialty pharmacy providers.

Adheris, an inVentiv Health company, announced today that Community Specialty Pharmacy Network, Inc (CSPN) has joined its growing network of over 21,000 pharmacies.

Diplomat Specialty Pharmacy--the nation's largest privately owned specialty pharmacy--recently announced that Steve Wolbert has been hired as its first Community Relations Liaison.

Through their studies of the molecular mechanisms involved in DNA repair, scientists from Case Western Reserve University School of Medicine found that the artificial activation of a gene called Chk1 permanently halts cancer cell replication.

Fresh on the heels of another failed drug trial, pharmaceutical companies try to gauge the remaining strategic options in the treatment of patients with Alzheimer's disease.

Teva Pharmaceutical Industries Ltd and Active Biotech announced they will continue the clinical development of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) in a third Phase III trial.

A new research and licensing partnership between the University of Pennsylvania and Novartis aims to develop more effective treatments for cancer by giving patients a disabled form of HIV.

The United States Food and Drug Administration approved Zaltrap (ziv-aflibercept) for use in combination with a Folfiri (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced publication of positive Phase 2 clinical data for Zevalin (ibritumomab tiuxetan) injection in patients with mantle-cell lymphoma.

GlaxoSmithKline plc announced regulatory submissions in the European Union and United States related to single-agent use of its BRAF inhibitor dabrafenib and MEK inhibitor trametinib to treat patients with BRAF V600 mutation positive metastatic melanoma.